Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Commentary|Videos|June 2, 2026
Dr Mascarenhas on Data for Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Author(s)John O. Mascarenhas, MD
Fact checked by: Chris Ryan, Ashling Wahner
John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.
Advertisement
John Mascarenhas, MD, a professor of medicine at the Icahn School of Medicine at Mount Sinai, director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and a member of Mount Sinai Tisch Cancer Center, discussed key data from the phase 3 SENTRY trial (NCT04562389) evaluating selinexor (Xpovio) plus ruxolitinib (Jakafi) in patients with JAK inhibitor–naïve myelofibrosis.
Advertisement
Related to this article
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5